Medication Management in Patients With Polypharmacy in Primary Care: A Scoping Review of Clinical Practice Guidelines

Abstract

Objective: Inappropriate polypharmacy increases the risk of medication-related issues. Adequate management of polypharmacy is a challenge involving different healthcare professionals, complex decision-making and ideally including patient involvement. The objective of this scoping review was to provide an overview of national recommendations for medication management of patients with polypharmacy in primary care.

Methods: A scoping review of clinical practice guidelines focusing on medication management in adults with polypharmacy, applicable to primary care was performed. Databases (G-I-N, Turning Research into Practice and PubMed), network, and a global report were screened for guidelines published after 2000 in English, Dutch, German, Spanish, French, or Russian. Raw data were extracted in duplicate using an extraction framework focusing on strategies, involvement of professionals, patient involvement, and implementation. Qualitative content analysis was used. Guideline quality was assessed using AGREE-II. The study was registered with the Open Science Framework.

Results: Eight guidelines originating from eight countries were included. The most common recommended strategy was a medication review conducted by a general practitioner and/or a community pharmacist. Tasks and target population differed per guideline. Most guidelines recommended involving the patient in the process, mostly to elicit the patient’s experiences and treatment goals. Few guidelines included advice on the implementation of recommendations. Three out of eight guidelines were of good quality (AGREE-II score >70% in 5/6 domains).

Conclusions: Most guidelines recommended a medication review, with patient involvement, as a strategy for medication management in polypharmacy in primary care. Guidance on task division and implementation of guidelines in practice was less clear. This review illustrates room for guideline improvements.

Keywords

medication therapy management / patient participation / polypharmacy / practice guideline / shared decision-making

References

[1] World Health Organization. Medication Safety in Polypharmacy: Technical Report (2019), https://www.who.int/docs/default-source/patient-safety/who-uhc-sds-2019-11-eng.pdf.

[2] P. Aggarwal,S. J. Woolford, and H. P. Patel,“Multi-Morbidity and Polypharmacy in Older People: Challenges and Opportunities for Clinical Practice, ” Geriatrics 5, no. 4 (2020):85.

[3] C. A. Cadogan,C. Ryan, and C. M. Hughes,“Appropriate Polypharmacy and Medicine Safety: When Many Is Not Too Many, ” Drug Safety 39, no. 2 (2016):109–116.

[4] M. Khezrian,C. J. McNeil,A. D. Murray, and P. K. Myint,“An Overview of Prevalence, Determinants and Health Outcomes of Polypharmacy, ” Therapeutic Advances in Drug Safety 11 (2020):2042098620933741.

[5] A. Mair,F. Fernandez-Llimos,A. Alonso, et al.,Polypharmacy Management by 2030: A Patient Safety Challenge (2017), https://www.isimpathy.eu/uploads/Polypharmacy-Handbook-2nd-Edition.pdf.

[6] R. W. Hoel,R. M. Giddings Connolly, and P. Y. Takahashi,“Polypharmacy Management in Older Patients, ” Mayo Clinic Proceedings 96, no. 1 (2021):242–256.

[7] T. R. Fried,J. O’Leary,V. Towle,M. K. Goldstein,M. Trentalange, and D. K. Martin,“Health Outcomes Associated With Polypharmacy in Community-Dwelling Older Adults: A Systematic Review, ” Journal of the American Geriatrics Society 62, no. 12 (2014):2261–2272.

[8] R. A. Payne,“The Epidemiology of Polypharmacy, ” Clinical Medicine (London, England) 16, no. 5 (2016):465.

[9] M. Kurczewska-Michalak,P. Lewek,B. Jankowska-Polańska, et al.,“Polypharmacy Management in the Older Adults: A Scoping Review of Available Interventions, ” Frontiers in Pharmacology 12 (2021):734045.

[10] C. Muth,J. W. Blom,S. M. Smith, et al.,“Evidence Supporting the Best Clinical Management of Patients With Multimorbidity and Polypharmacy: A Systematic Guideline Review and Expert Consensus, ” Journal of Internal Medicine 285, no. 3 (2019):272–288.

[11] N. Griese-Mammen,K. E. Hersberger,M. Messerli, et al.,“PCNE Definition of Medication Review: Reaching Agreement, ” International Journal of Clinical Pharmacy 40, no. 5 (2018):1199–1208.

[12] A. D. Meid,A. Lampert,A. Burnett,H. M. Seidling, and W. E. Haefeli,“The Impact of Pharmaceutical Care Interventions for Medication Underuse in Older People: A Systematic Review and Meta-Analysis, ” British Journal of Clinical Pharmacology 80, no. 4 (2015):768–776.

[13] V. J. B Huiskes,D. M. Burger,C. H. M. van den Ende, and B. J. F. van den Bemt,“Effectiveness of Medication Review: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, ” BMC Family Practice [Electronic Resource] 18, no. 1 (2017):1–15.

[14] R. Marchant,E. Thorman,E. Page, et al.,“Multidisciplinary Structured Medication Review Reduces Inappropriate Polypharmacy and Associated Costs in Care Homes, ” Age and Ageing 52, no. Supplement 2 (2023): afad104.013.

[15] K. P. Mc Namara,B. D. Breken,H. T. Alzubaidi, et al.,“Health Professional Perspectives on the Management of Multimorbidity and Polypharmacy for Older Patients in Australia, ” Age and Ageing 46, no. 2 (2017):291–299.

[16] J. Minshull and N. Barnett,“Managing Polypharmacy: Teamwork in General Practice, ” Prescriber 31, no. 1 (2020):25–29.

[17] B. Al-Babtain,E. Cheema, and M. A. Hadi,“Impact of Community-pharmacist-led Medication Review Programmes on Patient Outcomes: A Systematic Review and Meta-analysis of Randomised Controlled Trials, ” Research in Social and Administrative Pharmacy 18, no. 4 (2022):2559–2568.

[18] S. Verdoorn,H.-F. Kwint,J. W. Blom,J. Gussekloo, and M. L. Bouvy,“Effects of a Clinical Medication Review Focused on Personal Goals, Quality of Life, and Health Problems in Older Persons With Polypharmacy: A Randomised Controlled Trial (DREAMeR-study), ” PLoS Medicine 16, no. 5 (2019): e1002798.

[19] Z. Munn,M. D. Peters,C. Stern,C. Tufanaru,A. McArthur, and E. Aromataris,“Systematic Review or Scoping Review? Guidance for Authors When Choosing Between a Systematic or Scoping Review Approach, ” BMC Medical Research Methodology [Electronic Resource] 18, no. 143 (2018):1–7.

[20] A. C. Tricco,E. Lillie,W. Zarin, et al.,“PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation, ” Annals of Internal Medicine 169, no. 7 (2018):467–473.

[21] L. Engels,J. Jansen,H. E. Stoffers,P. Denig, and M. van den Akker,An International Comparison of National Guidelines on Medication Management in Patients With Polypharmacy in Primary Care: A Scoping Review protocol (Open Science Framework,2023), https://osf.io/a8qxw.

[22] R. Graham,M. Mancher,D. Miller Wolman, et al.,“Institute of Medicine, Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, ” Clinical Practice Guidelines We Can Trust (2011):0309164222, https://www.ncbi.nlm.nih.gov/books/NBK209539/.

[23] G-I-N Databse, https://g-i-n.net/international-guidelines-library.

[24] TRIP Database, https://www.tripdatabase.com/.

[25] PubMed, https://pubmed.ncbi.nlm.nih.gov/.

[26] A. Moser and I. Korstjens,“Series: Practical Guidance to Qualitative Research. Part 7: Qualitative Evidence Synthesis for Emerging Themes in Primary Care Research: Scoping Review, Meta-Ethnography and Rapid Realist Review, ” The European Journal of General Practice 29, no. 1 (2023):2274467.

[27] M. C. Brouwers,M. E. Kho,G. P. Browman, et al.,“AGREE II: Advancing Guideline Development, Reporting and Evaluation in Health Care, ” Cmaj 182, no. 18 (2010): E839–E842

[28] Dutch College of General Practitioners. Multidisciplinaire Richtlijn Polyfarmacie Bij Ouderen. [Multidisciplinary Guideline Polypharmacy in the Elderly]. 2012, https://richtlijnen.nhg.org/files/2021-02/2021-02-02%20%20Eindversie%20MDR%20Polyfarmacie.pdf.

[29] Dutch College of General Practitioners. Module Medicatiebeoordeling. Onderdeel Van De multidisciplinaire Richtlijn Polyfarmacie Bij Ouderen. [Medication Assessment Module. Part of the Multidisciplinary Guideline for Polypharmacy in the Elderly]. 2019, https://richtlijnen.nhg.org/files/2020-05/final_module_medicatiebeoordeling_2019.pdf.

[30] M. L Peralta-Pedrero,F. J Valdivia-Ibarra,M. Hernández-Manzano, et al.,“Guía de Práctica Clínica. Prescripción Farmacológica en el Adulto Mayor. [Clinical Practice Guide. Pharmacological Prescription in the Elderly], ” Revista médica del Instituto Mexicano del Seguro Social 51, no. 2 (2013):228–239.

[31] All Wales Medicines Strategy Group. Polypharmacy: Guidance for Prescribing. 2014, https://mipropiolio.wordpress.com/wp-content/uploads/2015/11/polypharmacy-guidance-for-prescribing.pdf.

[32] NICE Medicines and Prescribing Centre (UK). Medicines Optimisation: The Safe and Effective Use of Medicines to Enable the Best Possible Outcomes. 2015, https://www.nice.org.uk/guidance/ng5.

[33] Ministry of Health Labour and Welfare. Guidance on Appropriate Medication for Elderly Patients. 2018, https://www.pmda.go.jp/files/000232249.pdf.

[34] Scottish Government Polypharmacy Model of Care Group. Polypharmacy Guidance, Realistic Prescribing. 2018, https://www.therapeutics.scot.nhs.uk/wp-content/uploads/2018/04/Polypharmacy-Guidance-2018.pdf.

[35] Pharmaceutical Society of Australia. Guidelines for Comprehensive Medication Management Reviews. 2020, https://my.psa.org.au/s/article/guidelines-for-comprehensive-mmr.

[36] Leitiniengruppe Hessen. Hausärztliche Leitlinie Multimedikation. Empfehlungen zum Umgang mit Multimedikation bei Erwachsenen und Geriatrischen Patienten. [General Practitioner Guidelines on Multimedication. Recommendations for Dealing With Multimedication in Adults and Geriatric Patients]. 2021, https://register.awmf.org/assets/guidelines/053-043l_S3_Multimedikation_2021-08.pdf.

[37] N. P. Centre,Medicines Reconciliation: A Guide to Implementation (2008), https://www.nicpld.org/courses/fp/learning/assets/NPCMedicinesRecGuideImplementation.pdf.

[38] I. A. Scott,L. C. Gray,J. H. Martin, and C. A. Mitchell,“Minimizing Inappropriate Medications in Older Populations: A 10-Step Conceptual Framework, ” American Journal of Medicine 125, no. 6 (2012):529–537. e4.

[39] E. van Poelgeest,L. Seppala,G. Bahat, et al.,“Optimizing Pharmacotherapy and Deprescribing Strategies in Older Adults Living With Multimorbidity and Polypharmacy: EuGMS SIG on Pharmacology Position Paper, ” European Geriatric Medicine 14, no. 6 (2023):1195–1209.

[40] B. Abrahamsen,R. N. Hansen, and C. Rossing,“For Which Patient Subgroups Are There Positive Outcomes From a Medication Review? A Systematic Review, ” Pharmacy Practice 18, no. 4 (2020):1976.

[41] S. Crutzen,J. Schuling,J. G. Hugtenburg, et al.,“Development and Piloting of an Algorithm to Select Older Patients for Different Types of Medication Review, ” Frontiers in pharmacology 10 (2019):217.

[42] F. R. Gärtner,J. E. Portielje,M. Langendam, et al.,“Role of Patient Preferences in Clinical Practice Guidelines: A Multiple Methods Study Using Guidelines From Oncology as a Case, ” BMJ Open 9, no. 12 (2019): e032483.

[43] S. J. Liau,S. Lalic,J. K. Sluggett, et al.,“Medication Management in Frail Older People: Consensus Principles for Clinical Practice, Research, and Education, ” Journal of the American Medical Directors Association 22, no. 1 (2021):43–49.

[44] M. Petrovic,D. O’Mahony, and A. Cherubini,“Inappropriate Prescribing: Hazards and Solutions, ” Age and Ageing 51, no. 2 (2022): afab269.

[45] E. Radcliffe,R. Servin,N. Cox, et al.,“What Makes a Multidisciplinary Medication Review and Deprescribing Intervention for Older People Work Well in Primary Care? A Realist Review and Synthesis, ” BMC Geriatrics 23, no. 1 (2023):591.

[46] T. L Imfeld-Isenegger,I. B. Soares,U. N. Makovec, et al.,“Community Pharmacist-Led Medication Review Procedures Across Europe: Characterization, Implementation and Remuneration, ” Research in Social and Administrative Pharmacy 16, no. 8 (2020):1057–1066.

[47] S. Bartlett,“Practice-Based Pharmacists: Considerations for General Practices, ” British Journal of General Practice 73, no. 731 (2023):249–250.

[48] A. D. Oxman,P. Glasziou, and J. W. Williams,“What Should Clinicians Do When Faced With Conflicting Recommendations?, ” Bmj 337 (2008): a2530.

[49] F. Pazan and M. Wehling,“Polypharmacy in Older Adults: A Narrative Review of Definitions, Epidemiology and Consequences, ” European Geriatric Medicine 12 (2021):443–452.

[50] A. Mouazer,R. Tsopra,K. Sedki,C. Letord, and J.-B. Lamy,“Decision-Support Systems for Managing Polypharmacy in the Elderly: A Scoping Review, ” Journal of Biomedical Informatics 130 (2022):104074.

[51] Health SNBo, Welfare. Läkemedelsgenomgångar För Äldre Ordinerade Fem Eller Fler Läkemedel–en Vägledning För Hälso-och sjukvården [Medication Reviews for Elderly Persons Prescribed Five or More Medications—Guidelines for Health Services]. 2013, https://www.bpsd.se/wp-content/uploads/2010/05/L%E4kemedelsgenomg%E5ng-SoS.pdf.

[52] L. Albarqouni,S. Palagama,J. Chai, et al.,“Overuse of Medications in Low-and Middle-Income Countries: A Scoping Review, ” Bulletin of the World Health Organization 101, no. 1 (2022):36.

[53] U. Siering,M. Eikermann,E. Hausner,W. Hoffmann-Eßer, and E. A. Neugebauer,“Appraisal Tools for Clinical Practice Guidelines: A Systematic Review, ” PLoS ONE 8, no. 12 (2013): e82915.

RIGHTS & PERMISSIONS

2025 The Author(s). Journal of Evidence-Based Medicine published by Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.